Digital Diabetes Management Market Soars from $3.4 Billion in 2018 to Projected $17.1 Billion by 2026

The global digital diabetes management market has been on a significant growth trajectory, reflecting the escalating prevalence of diabetes worldwide. In 2018, this market was valued at a substantial $3,375.8 million, and it’s forecasted to soar to an impressive $17,118.7 million by 2026, driven by a remarkable compound annual growth rate (CAGR) of 22.5% from 2019 to 2026.

Diabetes, a chronic condition that disrupts the body’s glucose regulation, has become a widespread health concern. It often results from the pancreas’s inability to produce insulin or the body’s inability to maintain appropriate glucose levels. Alarming statistics from the World Health Organization (WHO) reveal the gravity of the situation. In 1980, a mere 108 million people were affected by diabetes, but by 2014, this number had surged to an alarming 422 million. This dramatic increase signifies a global prevalence rise from 4.7% to 8.5%.

Download Sample Report-  https://www.alliedmarketresearch.com/request-sample/6417

Key Market Players

DEXCOM, INC, F. HOFFMANN-LA ROCHE LTD., Johnson and Johnson, BECTON, DICKINSON AND COMPANY, NOVO NORDISK A/S, Abbott laboratories, Terumo corporation., ACON LABORATORIES, INC., Medtronic Plc., Bayer AG.

For Purchase Inquiry- https://www.alliedmarketresearch.com/digital-diabetes-management-market/purchase-options